Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Most economists expect muted U.S. economic growth in the coming quarters, and some indicators suggest a mild U.S. recession is still a possibility. It may become difficult for investors to ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug ...